Fosaprepitant
Emend, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Emend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
| Trade Name | Ivemend |
|---|---|
| Common Name | Fosaprepitant |
| Indication | neoplasms, vomiting |
| Drug Class | Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists; phosphoro-derivatives |
